Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570009 | 0.78 | CYP2D6 (0.44) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL18624716 | 0.72 | — | — | |
| SCHEMBL20363458 | 0.71 | CYP2D6 (0.38) | CYP2D6CYP2C19ADH1BADH1CADH1A | |
| SCHEMBL19449481 | 0.69 | TSHR (0.37) | — | |
| SCHEMBL18743123 | 0.68 | CYP2D6 (0.39) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL19670701 | 0.68 | CNR2 (0.41) | CYP2D6CYP2C19ADH1BADH1CADH1A | |
| SCHEMBL20821935 | 0.67 | CYP2D6 (0.31) | CYP2D6CYP2C19CNR2PPARGPPARD | |
| SCHEMBL23665700 | 0.67 | CYP2D6 (0.39) | CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL21167819 | 0.67 | — | — | |
| SCHEMBL18802668 | 0.67 | CA12 (0.39) | MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193246-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193246-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | UTRN, EDNRA, MTPN | CYP2D6 3527/4885CYP2C19 3228/4885ADH1B 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.